All In Biotech

Drug Trial Radar · NCT05907057

An Open-label Phase 3b Study of Ivosidenib in Combination With Azacitidine in Adult Patients Newly Diagnosed With IDH1m Acute Myeloid Leukemia (AML) Ineligible for Intensive Induction Chemotherapy.

A Single Arm, Open-label Phase 3b Study to Describe the Safety and Tolerability of Ivosidenib in Combination With Azacitidine in Adult Patients Newly Diagnosed With IDH1m Acute Myeloid Leukemia (AML) Ineligible for Intensive Induction Chemotherapy

Last checked: Nov 19, 2026Latest source record: May 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

245

Planned (sponsor's estimate)

Start

Jun 14, 2023

Primary completion

Oct 15, 2027

Study completion Oct 15, 2027

Sponsor

Lead sponsor
Servier Affaires MédicalesIndustry
Sponsor type
Industry
First posted
Jun 18, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to learn more about the safety and efficacy of ivosidenib taken with azacitidine to treat adult patients with acute myeloid leukemia (AML) who are presenting a gene mutation called IDH1 (isocitrate dehydrogenase1 mutation-positive \[IDH1m\]) and cannot receive treatment with intensive chemotherapy (IC).

Conditions

  • Acute Myeloid Leukemia (AML)

Interventions

  • Ivosidenib 500mg Oral TabletDrug

    Provided as tablets, taken orally as two 250mg tablets once daily.

  • AzacitidineDrug

    Administered subcutaneously (SC) or intravenously (IV) at a dose of 75mg/m2/day for 7 days, either consecutively on Days 1-7 or discontinuously for Days 1-5 and 8-9 of each cycle. The 7 days of administration will occur at the beginning of every 4 week-long cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Adverse Events (AEs)Time frame: up to week 116
  2. Number of Serious Adverse Events (SAEs)Time frame: up to week 116
  3. Differentiation Syndrome of Grade 2 or higherTime frame: up to week 116
  4. Number of Adverse Events (AEs) leading to ivosidenib + azacitidine discontinuationTime frame: up to week 112
  5. Number of Adverse Events (AEs) leading to ivosidenib + azacitidine interruptionTime frame: up to week 112
  6. Number of Adverse Events (AEs) leading to ivosidenib + azacitidine dose reductionTime frame: up to week 112
  7. Number of Adverse Events (AEs) leading to deathTime frame: up to week 116
  8. Number of clinical laboratory anomalies assessed as Adverse Events (AEs)Time frame: up to week 116
  9. Number of patients requiring transfusion (platelet and RBC) and the average number of units transfusedTime frame: up to week 116
  10. Rate of infectionsTime frame: up to week 116
  11. QT Prolongation event assessed as Grade 3 or higherTime frame: up to week 116

Locations

15 sites in 4 countries. Site status is shown where the registry gives one.

  • AKH - Medizinische Universität Wien

    Vienna, Austria · Completed

  • Klinikum Wels-Grieskirchen GmbH

    Wels, Austria · Completed

  • Institut Paoli Calmettes

    Marseille, Bouches-du-Rhône, France · Recruiting

  • CHU CAEN - Hôpital de la Côte de Nacre

    Caen, Calvados, France · Recruiting

  • CHU de Toulouse pt

    Toulouse, Haute Garonne, France · Recruiting

  • CHU Rennes - Hopital Pontchaillou

    Rennes, Ille Et Vilaine, France · Not yet recruiting

  • CHU Angers - Hôpital Hôtel Dieu

    Angers, Liore, France · Not yet recruiting

  • Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia (Presidio Spedali Civili)

    Brescia, Italy · Recruiting

  • IRCCS Ospedale Policlinico San Martino

    Genova, Italy · Recruiting

  • Azienda Ospedaliera di Perugia Ospedale S. Maria della Misericordia

    Perugia, Italy · Recruiting

  • IRCCS Istituto Scientifico Romagnolo Per Lo Studio Dei Tumori "Dino Amadori" - IRST

    Meldola, Forli-Cesena, Italy · Recruiting

  • Meander Medisch Centrum

    Amersfoort, Netherlands · Recruiting

  • Amsterdam UMC

    Amsterdam, Netherlands · Recruiting

  • Rijnstate

    Arnhem, Netherlands · Not yet recruiting

  • Universitair Medisch Centrum Groningen

    Groningen, Netherlands · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.